{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:44:46Z","timestamp":1794041086990,"version":"4.8.0"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"40","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Some reports have pointed out that calcimimetics agents are effective in the treatment of\nsecondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, but there is no detailed description\nof the advantages and disadvantages of calcimimetics agents of SHPT in CKD patients. We tried to pool\nthe published data to verify the effectiveness of calcimimetics agents and to compare the advantages and disadvantages\nof cinacalcet compared with control in the treatment of SHPT in CKD patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We included eligible studies of published papers from January 1st, 2000 to December 31st, 2020 in\nMedline, Pubmed and Web of science databases, and the data were extracted for this meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Twenty-seven studies were eligible, and all the included studies were randomized controlled trials\n(RCT) including patients treated with long-term dialysis. The results indicated that calcimimetic agents can\nreduce the parathyroid hormone (PTH, pg\/ml) level (WMD = -178.22, 95% CI: -238.57, -117.86, P &lt; 0.00001),\ncalcium (Ca, mg\/dl) level (WMD = -0.71, 95% CI: -0.86, -0.55, P &lt; 0.00001), phosphorus (P, mg\/dl) level\n(WMD = -0.32, 95% CI: -0.55, -0.08, P = 0.008), calcium-phosphorus product level (WMD = -7.73, 95% CI:\n-9.64, -5.82, P &lt; 0.00001). Calcimimetic agents increased the bone alkaline phosphatase (BSAP, ng\/ml) levels\nand rate of achieving target PTH, and reduced osteocalcin levels and the rate of parathyroidectomy. Calcimimetic\nagents increased the total adverse events\u2019 rate, the rate of hypocalcemia and gastrointestinal side effects\n(nausea, vomiting, abdominal pain and diarrhea), but there was no significant difference in serious adverse\nevents between the calcimimetic agent group and control group.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Calcimimetic agents can reduce the PTH level, Ca level, P level, calcium-phosphorus product\nlevel and do not increase serious adverse events.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612829666221027110656","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T07:22:33Z","timestamp":1666941753000},"page":"3289-3304","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic\nAgents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic\nKidney Disease"],"prefix":"10.2174","volume":"28","author":[{"given":"Yiping","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital, Shantou University Medical College, 515041, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital, Shantou University Medical College, 515041, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital, Shantou University Medical College, 515041, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital, Shantou University Medical College, 515041, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"Cunningham J.","year":"2011","unstructured":"Cunningham J.; Locatelli F.; Rodriguez M.; Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011,6(4),913-921","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017,7(1),1-59","journal-title":"Kidney Int Suppl"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","volume":"31","author":"Leifheit-Nestler M","year":"2016","unstructured":"Leifheit-Nestler M; gro\u00dfe Siemer R; Flasbart K; Induction of cardiac fgf23\/fgfr4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 2016,31(7),1088-1099","journal-title":"Nephrol Dial Transplant"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/ndt\/gft456","volume":"29","author":"Bouma-de Krijger A.","year":"2014","unstructured":"Bouma-de Krijger A.; Bots M.L.; Vervloet M.G.; Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant 2014,29(1),88-97","journal-title":"Nephrol Dial Transplant"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/13543784.2014.962652","volume":"23","author":"Cernaro V.","year":"2014","unstructured":"Cernaro V.; Santoro D.; Lucisano S.; Nicocia G.; Lacquaniti A.; Buemi M.; The future of phosphate binders: A perspective on novel therapeutics. Expert Opin Investig Drugs 2014,23(11),1459-1463","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","volume":"58","author":"Goodman W.G.","year":"2000","unstructured":"Goodman W.G.; Frazao J.M.; Goodkin D.A.; Turner S.A.; Liu W.; Coburn J.W.; A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000,58(1),436-445","journal-title":"Kidney Int"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"Goodman W.G.","year":"2002","unstructured":"Goodman W.G.; Hladik G.A.; Turner S.A.; The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002,13(4),1017-1024","journal-title":"J Am Soc Nephrol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"Lindberg J.S.","year":"2003","unstructured":"Lindberg J.S.; Moe S.M.; Goodman W.G.; The calcimimetic AMG 073 reduces parathyroid hormone and calcium X phosphorus in secondary hyperparathyroidism. Kidney Int 2003,63(1),248-254","journal-title":"Kidney Int"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","volume":"14","author":"Quarles L.D.","year":"2003","unstructured":"Quarles L.D.; Sherrard D.J.; Adler S.; The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003,14(3),575-583","journal-title":"J Am Soc Nephrol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"Block G.A.","year":"2004","unstructured":"Block G.A.; Martin K.J.; de Francisco A.L.M.; Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004,350(15),1516-1525","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","volume":"44","author":"Harris R.Z.","year":"2004","unstructured":"Harris R.Z.; Padhi D.; Marbury T.C.; Noveck R.J.; Salfi M.; Sullivan J.T.; Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004,44(6),1070-1076","journal-title":"Am J Kidney Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","volume":"46","author":"Charytan C.","year":"2005","unstructured":"Charytan C.; Coburn J.W.; Chonchol M.; Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with ckd not receiving dialysis. Am J Kidney Dis 2005,46(1),58-67","journal-title":"Am J Kidney Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"Lindberg J.S.","year":"2005","unstructured":"Lindberg J.S.; Culleton B.; Wong G.; Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005,16(3),800-807","journal-title":"J Am Soc Nephrol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"Fishbane S.","year":"2008","unstructured":"Fishbane S.; Shapiro W.B.; Corry D.B.; Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The achieve study results. Clin J Am Soc Nephrol 2008,3(6),1718-1725","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1744-9987.2008.00556.x","volume":"12","author":"Akiba T.","year":"2008","unstructured":"Akiba T.; Akizawa T.; Tsukamoto Y.; Uchida E.; Iwasaki M.; Koshikawa S.; Dose determination of cinacalcet hydrochloride in japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2008,12(2),117-125","journal-title":"Ther Apher Dial"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"Fukagawa M.","year":"2007","unstructured":"Fukagawa M.; Yumita S.; Akizawa T.; Cinacalcet (KRN1493) effectively decreases the serum intact pth level with favourable control of the serum phosphorus and calcium levels in japanese dialysis patients. Nephrol Dial Transplant 2007,23(1),328-335","journal-title":"Nephrol Dial Transplant"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"Messa P.","year":"2008","unstructured":"Messa P.; Mac\u00e1rio F.; Yaqoob M.; The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008,3(1),36-45","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","volume":"53","author":"Chonchol M.","year":"2009","unstructured":"Chonchol M.; Locatelli F.; Abboud H.E.; A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCL in participants with ckd not receiving dialysis. Am J Kidney Dis 2009,53(2),197-207","journal-title":"Am J Kidney Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"Raggi P.","year":"2011","unstructured":"Raggi P.; Chertow G.M.; Torres P.U.; The Advance study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011,26(4),1327-1339","journal-title":"Nephrol Dial Transplant"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1744-9987.2011.00994.x","volume":"15","author":"El-Shafey E.M.","year":"2011","unstructured":"El-Shafey E.M.; Alsahow A.E.; Alsaran K.; Sabry A.A.; Atia M.; Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 2011,15(6),547-555","journal-title":"Ther Apher Dial"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"Chertow G.M.","year":"2012","unstructured":"Chertow G.M.; Block G.A.; Correa-Rotter R.; Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012,367(26),2482-2494","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"Ketteler M.","year":"2012","unstructured":"Ketteler M.; Martin K.J.; Wolf M.; Paricalcitol versus cinacalcet plus low-dose vitamin d therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the Impact SHPT study. Nephrol Dial Transplant 2012,27(8),3270-3278","journal-title":"Nephrol Dial Transplant"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2369-14-112","volume":"14","author":"Kim H.J.","year":"2013","unstructured":"Kim H.J.; Kim H.; Shin N.; Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: A randomized controlled study. BMC Nephrol 2013,14(1),112","journal-title":"BMC Nephrol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","volume":"28","author":"Ure\u00f1a-Torres P.","year":"2013","unstructured":"Ure\u00f1a-Torres P.; Bridges I.; Christiano C.; Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant 2013,28(5),1241-1254","journal-title":"Nephrol Dial Transplant"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"Bell G.","year":"2015","unstructured":"Bell G.; Huang S.; Martin K.J.; Block G.A.; A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 2015,31(5),943-952","journal-title":"Curr Med Res Opin"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/hdi.12410","volume":"20","author":"Mei C.","year":"2016","unstructured":"Mei C.; Chen N.; Ding X.; Efficacy and safety of cinacalcet on secondary hyperparathyroidism in chinese chronic kidney disease patients receiving hemodialysis. Hemodial Int 2016,20(4),589-600","journal-title":"Hemodial Int"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ekir.2017.01.016","volume":"2","author":"Yokoyama K.","year":"2017","unstructured":"Yokoyama K.; Fukagawa M.; Shigematsu T.; A single and multiple dose, multicenter study of etelcalcetide in japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int Rep 2017,2(4),634-644","journal-title":"Kidney Int Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"Block G.A.","year":"2017","unstructured":"Block G.A.; Bushinsky D.A.; Cunningham J.; Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism. JAMA 2017,317(2),146-155","journal-title":"JAMA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"gfw408","DOI":"10.1093\/ndt\/gfw408","volume":"32","author":"Fukagawa M.","year":"2017","unstructured":"Fukagawa M.; Yokoyama K.; Shigematsu T.; A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 2017,32(10),gfw408","journal-title":"Nephrol Dial Transplant"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e0204896","DOI":"10.1371\/journal.pone.0204896","volume":"13","author":"Akizawa T.","year":"2018","unstructured":"Akizawa T.; Shimazaki R.; Fukagawa M.; Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One 2018,13(10),e0204896","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"Fukagawa M.","year":"2018","unstructured":"Fukagawa M.; Shimazaki R.; Akizawa T.; Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2018,94(4),818-825","journal-title":"Kidney Int"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/0886022X.2018.1562356","volume":"41","author":"Susantitaphong P.","year":"2019","unstructured":"Susantitaphong P.; Vadcharavivad S.; Susomboon T.; The effectiveness of cinacalcet: A randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail 2019,41(1),326-333","journal-title":"Ren Fail"},{"key":"ref=33","first-page":"1779","volume":"11","author":"Sternlicht H.","year":"2015","unstructured":"Sternlicht H.; Glezerman I.G.; Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag 2015,11,1779-1788","journal-title":"Ther Clin Risk Manag"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","volume":"35","author":"Bushinsky D.A.","year":"2020","unstructured":"Bushinsky D.A.; Chertow G.M.; Cheng S.; One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant 2020,35(10),1769-1778","journal-title":"Nephrol Dial Transplant"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-019-1639-9","volume":"21","author":"Sun Y.","year":"2020","unstructured":"Sun Y.; Tian B.; Sheng Z.; Wan P.; Xu T.; Yao L.; Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: A meta-analysis. BMC Nephrol 2020,21(1),316","journal-title":"BMC Nephrol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2217\/cer-2018-0015","volume":"7","author":"Lozano-Ortega G.","year":"2018","unstructured":"Lozano-Ortega G.; Waser N.; Bensink M.E.; Effects of calcimimetics on long-term outcomes in dialysis patients: Literature review and bayesian meta-analysis. J Comp Eff Res 2018,7(7),693-707","journal-title":"J Comp Eff Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","volume":"76","author":"Palmer S.C.","year":"2020","unstructured":"Palmer S.C.; Mavridis D.; Johnson D.W.; Tonelli M.; Ruospo M.; Strippoli G.F.M.; Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis 2020,76(3),321-330","journal-title":"Am J Kidney Dis"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221027110656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210412\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221027110656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:16:36Z","timestamp":1691727396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210412\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666221027110656","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}